Dynamic prediction of relapse in patients with acute leukemias after allogeneic transplantation: Joint model for minimal residual disease

2020 ◽  
Author(s):  
Aijie Huang ◽  
Qi Chen ◽  
Yang Fei ◽  
Ziwei Wang ◽  
Xiong Ni ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
Allogeneic Transplantation ◽  
Joint Model ◽  
Dynamic Prediction ◽  
Acute Leukemias ◽  
Prediction Of Relapse ◽  
Minimal Residual

ACUTE LEUKEMIAS 2019: Risikofaktor MRD eröffnet neue Perspektiven

2019 ◽  
Vol 10 (04) ◽  
pp. 158-160
Author(s):  
Ulrike Röper
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
Individualisierte Therapie ◽  
Acute Leukemias ◽  
Minimal Residual

Weiterentwicklungen in der Molekulardiagnostik ermöglichen zuverlässigere Aussagen zur Differenzialdiagnostik maligner Erkrankungen. Sie sind Meilensteine für eine individualisierte Therapie. Darüber hinaus zeigt sich ihre zunehmende Bedeutung für prognostische Einschätzungen. Die Kontrolle der minimalen Resterkrankung (Minimal Residual Disease; MRD) rückt zunehmend in den Fokus, auch wenn noch viele Fragen zu klären sind.

Minimal Residual Disease in Hematologic Disorders

1999 ◽  
Vol 123 (11) ◽  
pp. 1030-1034
Author(s):  
Stefan Faderl ◽  
Razelle Kurzrock ◽  
Zeev Estrov
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
Chemotherapeutic Agents ◽  
New Drugs ◽  
Myelogenous Leukemia ◽  
Therapeutic Success ◽  
Acute Leukemias ◽  
Hematologic Disorders ◽  
Kinetics Of ◽  
Minimal Residual

Abstract In almost no other area of medical oncology has the introduction of new drugs, combinations of chemotherapeutic agents, and novel biologic treatments caused such dramatic responses as it has in the treatment of malignant hematologic disorders. However, despite some therapeutic success, many patients relapse and die from recurrence of their disease. The implications of minimal residual disease (MRD), a term referring to disease that is undetectable by conventional morphologic methods, have therefore attracted increasing attention in recent years. New and powerful laboratory tools such as polymerase chain reaction assays have extraordinary sensitivity and provide exciting new insights into the detection, nature, quantification, and kinetics of MRD. This article summarizes methods used in the identification of MRD and its importance as exemplified in the case of acute leukemias and chronic myelogenous leukemia.

scholarly journals Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations

Leukemia ◽  
2006 ◽  
Vol 20 (3) ◽  
pp. 451-457 ◽  
Author(s):  
T Burmeister ◽  
R Marschalek ◽  
B Schneider ◽  
C Meyer ◽  
N Gökbuget ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
Acute Leukemias ◽  
Chromosomal Breakpoint ◽  
Minimal Residual

Monitoring of BCR-ABL Transcirpt Levels after Discontinuation of Imatinib Therapy in Chronic Myelogenous Leukemia Patients Achieving Complete Cytogenetic Response.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4684-4684 ◽  
Author(s):  
Yoo-Jin Kim ◽  
Dong-Wook Kim ◽  
Seok Lee ◽  
Ki-Seong Eom ◽  
Chang-Ki Min ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Chronic Myelogenous Leukemia ◽  
Residual Disease ◽  
Transcript Level ◽  
Allogeneic Transplantation ◽  
Cytogenetic Response ◽  
Myelogenous Leukemia ◽  
Imatinib Treatment ◽  
Rt Pcr ◽  
Minimal Residual

Abstract Background Imatinib induces a high complete cytogenetic response (CCR) rate in chronic myelogenous leukemia (CML). None of the studies addressed the important question of how long imatinib treatment should be continued. To answer this question, we tried to assess the minimal residual disease after cessation of imatinib in patients achieving CCR. Methods A total of 23 patients were enrolled and their disease status at the start of imatinib was chronic phase in 7, accelerated phase in 3, blast crisis in 1, and post-transplant relapse in 12 patients. All the patients were in CCR when imatinib was discontinued and BCR-ABL transcript was undetectable in 9 of them. Minimal residual disease was monitored using nested RT-PCR, real-time quantitative RT-PCR, and conventional cytogenetics. Findings Duration of imatinb treatment and CCR before cessation of imatnib was a median of 13 months (range, 6–25 months) and 10 months (range, 1–22 months), respectively. After cessation of imatinib treatment, cytogenetic relapse was observed in 12 (53%) of 23 patients and hematological relapse was followed in 8 (67%) of them. Extramedullary relapse was documented in 1 patient. Prior allogenetic transplantation, molecular remission at the time of cessation, and time to CCR were potential variables affecting probability of cytogenetic relapse. Normalized BCR-ABL transcript level progressively increased after cessation of imatinib in all but 3 patients who had been treated with allogeneic transplantation. Restart of imatinib induced down-regulation of normalized BCR-ABL transcript level in 5 patients with available data. Interpretation Imatnib should be maintained in the most of patients who achieve a short duration of CCR as in the cases with interferon treatment. However, this study suggests that it seems possible to stop imatinib treatment in the minority of CML patients who was treated with allogeneic transplantation.

Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation

2005 ◽  
Vol 29 (8) ◽  
pp. 961-966 ◽  
Author(s):  
Sara Galimberti ◽  
Edoardo Benedetti ◽  
Fortunato Morabito ◽  
Federico Papineschi ◽  
Vincenzo Callea ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Allogeneic Transplantation ◽  
Prognostic Role ◽  
Minimal Residual
Sign in / Sign up

Export Citation Format

Share Document